We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Australian Fee Change Plan Benefits Some Devicemakers

Australian Fee Change Plan Benefits Some Devicemakers

May 15, 2015

Australia’s Therapeutic Goods Administration is proposing changes to its low-value turnover exemption scheme that could help some devicemakers save money while reducing red tape and making the process more user-friendly and transparent.

The government levies annual charges to recover the costs of certain regulatory functions for medical devices and other products listed on the Australian Register of Therapeutic Goods.

The current scheme allows firms to avoid those charges if their annual sales turnover is less than or equal to 15 times the fee. Because of the burden involved in preparing and submitting an application, some companies are discouraged from seeking the exemption, the TGA says.

Under the revised scheme, the exemption would be replaced by an annual charge exemption, or ACE. Devicemakers could self-declare that they had zero dollars of sales turnover in the previous fiscal year to qualify for the exemption, rather than having to obtain a third-party accountant’s certification. The government would conduct audits to detect incorrect declarations.

The new scheme would simplify the exemption process for devicemakers and the TGA by eliminating applications and application fees and not requiring approval by a delegate of the health secretary, the TGA says.

The Federal Executive Council is expected to consider the proposal before June 30, says TGA spokesman Neil Branch. Once approved, the agency will provide guidance to industry.

Starting next month, the TGA plans to inform devicemakers of eligibility for an initial ACE, with plans to implement the scheme on July 1. Sponsors would be required to self-declare on an annual basis between July 1 and July 22 starting next year. Annual charges would be due Sept. 15.

Read the regulation impact statement and Q&A document at www.fdanews.com/5-15-TGA-ACE.pdf and www.fdanews.com/5-15-TGA-ACE-QA.pdf, respectively. — Jonathon Shacat

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing